Development of a vaccine for genital chlamydia infections: protection against transmission and disease pathology

生殖器衣原体感染是澳大利亚最常见的性传播感染，每年的医疗费用为9000万至1.6亿美元。15-29岁人群的感染率正以每年15-20%的速度增长。抗生素是目前的治疗选择，然而抗生素耐药性正在增加，大多数感染是无症状的，在缺乏筛查计划的情况下没有得到治疗。该项目旨在开发一种使用新抗原组合的生殖器衣原体疫苗。

Genital Chlamydia infections are the most common sexually transmitted infection in Australia with annual health costs of 90-160 million dollars. Ifection rates in 15-29 year olds are increasing at 15-20% per year. Antibiotics are currently the treatment of choice, however antibiotic resistance is increasing and most infections are asymptomatic and not treated in the absence of screening programs. The project aims to develop a genital Chlamydia vaccine using a combination of novel antigens.